Brachytherapy technology now available nationwide
TargetScan, a new device that provides a stationary probe to eliminate prostate movement during certain prostate cancer treatments, will now be distributed to physicians nationwide through an exclusive agreement between Envisioneering Medical Technologies, the product?s developer, and BrachySciences.
TargetScan, a new device that provides a stationary probe to eliminate prostate movement during certain prostate cancer treatments, will now be distributed to physicians nationwide through an exclusive agreement between Envisioneering Medical Technologies, the product’s developer, and BrachySciences.
“This agreement places new technology that can improve prostate cancer treatment outcomes directly in the hands of doctors to benefit their patients,” said Robert G. Mills, Envisioneering president.
According to Mills, TargetScan addresses unmet treatment planning and brachytherapy seed placement needs of radiation oncologists. In addition to eliminating prostate movement during treatments, the system offers improved 3-D imaging, with views of both sagittal and transverse planes.
Pediatric urinary microbiome composition is associated with recurrent UTI
September 10th 2024“We hope to learn more about the urinary tract and then be able to correlate predisposition to UTIs or other urological conditions with urobiome composition or marker microbe presence,” says Tatyana A. Sysoeva, PhD.
Advancing bladder cancer care: The importance of integrating mental health support
September 9th 2024"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.
